Precigen (NASDAQ:PGEN) COO Sells $224,589.54 in Stock

07 Aug 2026, 23:08 by Sarita Garza · The Markets Daily

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) COO Rutul Shah sold 32,739 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $6.86, for a total value of $224,589.54. Following the completion of the transaction, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at $3,189,982.32. The trade was a 6.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Price Performance

PGEN traded up $0.32 during trading on Friday, hitting $7.23. The company’s stock had a trading volume of 5,754,727 shares, compared to its average volume of 4,614,801. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -6.95 and a beta of 1.02. Precigen, Inc. has a twelve month low of $1.70 and a twelve month high of $7.26. The business’s fifty day simple moving average is $5.17 and its 200 day simple moving average is $4.48. The company has a current ratio of 4.58, a quick ratio of 4.12 and a debt-to-equity ratio of 2.15.

Precigen (NASDAQ:PGEN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The business had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen’s revenue was up 6322.7% on a year-over-year basis. On average, equities research analysts forecast that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Wall Street Analysts Forecast Growth

PGEN has been the topic of several recent analyst reports. Citizens Jmp increased their price objective on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. HC Wainwright upped their price target on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Precigen presently has an average rating of “Moderate Buy” and an average price target of $14.50.

Read Our Latest Research Report on PGEN

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State of Wyoming purchased a new stake in shares of Precigen in the 1st quarter valued at approximately $27,000. NBC Securities Inc. purchased a new stake in shares of Precigen during the 4th quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new position in Precigen in the third quarter valued at approximately $39,000. Royal Bank of Canada grew its position in Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,426 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Precigen in the third quarter worth approximately $41,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.